On February 28, 2022 ​Imago BioSciences, Inc. ("Imago") (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), reported that Hugh Y. Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in the Cowen 42nd Annual Health Care Conference, taking place March 7-9, 2022 (Press release, Imago BioSciences, FEB 28, 2022, View Source [SID1234609130]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Rienhoff is scheduled to participate in the "Leukemias and Myeloproliferative Neoplasms" corporate panel discussion, on Monday, March 7, at 10:30 a.m. Eastern Time.

Interested parties can access the live webcast for this conference from the Investor Relations section of the company’s website at www.imagobio.com. The webcast replay will be available after the conclusion of the panel discussion for approximately 30 days.